secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0000950170-23-008163
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences Q4/Full Year 2022 Net Loss $58.8M; Phase 3 Trial on Track, FDA Fast Track for Choroidal Metastasis
--------------------------------------------------------------------------------

- Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.
- FDA granted Fast Track Designation for bel-sar in choroidal metastasis, second ocular oncology indication.
- Global Phase 3 trial in early-stage choroidal melanoma on track to dose first patient in 1H 2023.
- Positive interim Phase 2 data: 100% tumor control rate, statistically significant reduction in growth rate (p<0.0001) at 9-month follow-up.
- Raised $92.5M gross proceeds in oversubscribed follow-on public offering in December 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/0000950170-23-008163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023008163/aura-20230315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer